Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Compromised chronic efficacy of a glucokinase activator AZD1656 in mouse models for common human GCKR variants.

Biochemical pharmacology - 1 Nov 2024

Ford Brian E, Chachra Shruti S, Alshawi Ahmed, Oakley Fiona, Fairclough Rebecca J, Smith David M, Tiniakos Dina, Agius Loranne

Abstract excerpt

Glucokinase activators (GKAs) have been developed as blood glucose lowering drugs for type 2 diabetes. Despite good short-term efficacy, several GKAs showed a decline in efficacy chronically during clinical trials. The underlying mechanisms remain incompletely understood. We tested the hypothesis that deficiency in the liver glucokinase regulatory protein (GKRP) as occurs with common human GCKR variants affects...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adaptor Proteins, Signal Transducing
Share to Azetidines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Blood Glucose

Share to Diabetes Mellitus, Type 2

Share to Glucokinase

Share to Hypoglycemic Agents

Share to Pyrazines

Source

Identifiers

PMID: 39173844
DOI: 10.1016/j.bcp.2024.116499

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Compromised chronic efficacy of a glucokinase activator AZD1656 in mouse models for common human GCKR variants.PMID 39173844Read ↗

Compromised chronic efficacy of a Glucokinase Activator AZD1656 in mouse models for common human <i>GCKR</i> variantsSemantic proximity Read ↗

The GCKR-P446L gene variant predisposes to raised blood cholesterol and lower blood glucose in the P446L mouse-a model for GCKR rs1260326Semantic proximity Read ↗

Glucokinase activity suppresses hepatic cholesterol synthesis and triglyceride accumulation: A new model for the effects of the GKRP P466L common human variantSemantic proximity Read ↗

The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver.Semantic proximity Read ↗

Recent clinical advances of glucokinase activators in the treatment of diabetes mellitus type 2.Semantic proximity Read ↗

Genotype-phenotype discrepancy among family members carrying a novel glucokinase mutation: insights into the interplay of GCK-MODY and insulin resistanceSemantic proximity Read ↗

New-Generation Glucokinase Activators: Potential Game-Changers in Type 2 Diabetes TreatmentSemantic proximity Read ↗

From clinicogenetic studies of maturity-onset diabetes of the young to unraveling complex mechanisms of glucokinase regulation.Semantic proximity Read ↗

Impaired GK-GKRP interaction rather than direct GK activation worsens lipid profiles and contributes to long-term complications: a Mendelian randomization study.Semantic proximity Read ↗

Characterizing glucokinase variant mechanisms using a multiplexed abundance assaySemantic proximity Read ↗

Characterizing glucokinase variant mechanisms using a multiplexed abundance assay.Semantic proximity Read ↗

Glucokinase Inactivation Ameliorates Lipid Accumulation and Exerts Favorable Effects on Lipid Metabolism in Hepatocytes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.